Share on StockTwits

Endocyte (NASDAQ:ECYT) issued its quarterly earnings data on Tuesday. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.42, American Banking News reports. The company had revenue of $49.17 million for the quarter, compared to the consensus estimate of $26.62 million. The company’s revenue for the quarter was up 198.4% on a year-over-year basis.

A number of research firms have recently commented on ECYT. Analysts at Brean Capital initiated coverage on shares of Endocyte in a research note on Tuesday, July 8th. They set a “buy” rating and a $22.00 price target on the stock. On a related note, analysts at Zacks upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating in a research note on Monday, July 7th. They now have a $7.90 price target on the stock. Finally, analysts at Chardan Capital cut their price target on shares of Endocyte from $26.00 to $15.00 in a research note on Wednesday, June 18th. They now have a “buy” rating on the stock. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.49.

Shares of Endocyte (NASDAQ:ECYT) traded up 2.68% on Tuesday, hitting $6.12. 723,545 shares of the company’s stock traded hands. Endocyte has a 52 week low of $5.91 and a 52 week high of $33.70. The stock’s 50-day moving average is $6.50 and its 200-day moving average is $11.97. The company’s market cap is $254.0 million.

Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.